2017
DOI: 10.3348/kjr.2017.18.1.84
|View full text |Cite
|
Sign up to set email alerts
|

Update on Gastrointestinal Stromal Tumors for Radiologists

Abstract: The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
31
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 33 publications
(32 citation statements)
references
References 48 publications
(86 reference statements)
0
31
0
Order By: Relevance
“…Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. Risk stratification of GISTs tries to evaluate the risk of poor outcome and to choose patients who may benefit from adjuvant therapy [1]. Although criteria may vary from country to country, the 2008 National Institute of Health (NIH) criteria are the most widely used.…”
Section: Introductionmentioning
confidence: 99%
“…Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. Risk stratification of GISTs tries to evaluate the risk of poor outcome and to choose patients who may benefit from adjuvant therapy [1]. Although criteria may vary from country to country, the 2008 National Institute of Health (NIH) criteria are the most widely used.…”
Section: Introductionmentioning
confidence: 99%
“…Zhou et al . regarded EVFDM as a predictor for risk stratification 12 , although the exact mechanism underlying this relationship is unclear and needs further study 13,14 .…”
Section: Discussionmentioning
confidence: 99%
“…However, the response was unique as compared with conventional chemotherapy as there was often little initial shrinkage in the tumor size, but with dramatic decrease in tumor enhancement and inhomogeneity. 1,2 The tumors appeared well defined, homogeneous, and hypodense (almost cystic in appearance) after initiation of treatment with imatinib. This is due to the development of cystic or myxoid change within the tumor without significant necrosis or inflammation.…”
Section: Therapy-specific Criteria Choi Criteriamentioning
confidence: 99%